263 related articles for article (PubMed ID: 33159658)
1. Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial.
Shi A; Xie P; Nielsen LL; Skjøth TV; He X; Haugaard SP
Adv Ther; 2021 Jan; 38(1):550-561. PubMed ID: 33159658
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Enebo LB; Berthelsen KK; Kankam M; Lund MT; Rubino DM; Satylganova A; Lau DCW
Lancet; 2021 May; 397(10286):1736-1748. PubMed ID: 33894838
[TBL] [Abstract][Full Text] [Related]
3. A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects.
Ikushima I; Jensen L; Flint A; Nishida T; Zacho J; Irie S
Adv Ther; 2018 Apr; 35(4):531-544. PubMed ID: 29536338
[TBL] [Abstract][Full Text] [Related]
4. A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects.
Xie P; Abildlund MT; Bækdal TA; He X; Lyauk YK; Patted URH; Ning Z; Shi A
Diabetes Obes Metab; 2024 May; ():. PubMed ID: 38808476
[TBL] [Abstract][Full Text] [Related]
5. Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes.
Granhall C; Donsmark M; Blicher TM; Golor G; Søndergaard FL; Thomsen M; Bækdal TA
Clin Pharmacokinet; 2019 Jun; 58(6):781-791. PubMed ID: 30565096
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
7. Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects.
van Hout M; Forte P; Jensen TB; Boschini C; Bækdal TA
Clin Pharmacokinet; 2023 Apr; 62(4):635-644. PubMed ID: 36932262
[TBL] [Abstract][Full Text] [Related]
8. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
[TBL] [Abstract][Full Text] [Related]
9. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.
Marbury TC; Flint A; Jacobsen JB; Derving Karsbøl J; Lasseter K
Clin Pharmacokinet; 2017 Nov; 56(11):1381-1390. PubMed ID: 28349386
[TBL] [Abstract][Full Text] [Related]
11. Dose-response effects on HbA
Blüher M; Rosenstock J; Hoefler J; Manuel R; Hennige AM
Diabetologia; 2024 Mar; 67(3):470-482. PubMed ID: 38095657
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
[TBL] [Abstract][Full Text] [Related]
14. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.
Kapitza C; Dahl K; Jacobsen JB; Axelsen MB; Flint A
Diabetologia; 2017 Aug; 60(8):1390-1399. PubMed ID: 28526920
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.
Jensen L; Kupcova V; Arold G; Pettersson J; Hjerpsted JB
Diabetes Obes Metab; 2018 Apr; 20(4):998-1005. PubMed ID: 29205786
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes.
Asano M; Sekikawa A; Kim H; Gasser RA; Robertson D; Petrone M; Jermutus L; Ambery P
Diabetes Obes Metab; 2021 Aug; 23(8):1859-1867. PubMed ID: 33908687
[TBL] [Abstract][Full Text] [Related]
18. Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration.
Granhall C; Bækdal TA; Breitschaft A; Søndergaard FL; Anderson TW; Thomsen M
Diabetes Ther; 2021 Sep; 12(9):2599-2610. PubMed ID: 34319564
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study.
Xu J; Zhang Y; Li Y; Zhao X; Zhou W; Loghin C; Tham LS; Cui X; Cui Y; Wang W
Adv Ther; 2022 Jan; 39(1):488-503. PubMed ID: 34787823
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.
Mu Y; Bao X; Eliaschewitz FG; Hansen MR; Kim BT; Koroleva A; Ma RCW; Yang T; Zu N; Liu M;
Lancet Diabetes Endocrinol; 2024 Mar; 12(3):184-195. PubMed ID: 38330988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
